A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis

Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor currently being investigated as a treatment for anemia of chronic kidney disease (CKD) in both dialysis and nondialysis patients. In clini...

Source: BMC Nephrology - October 16, 2019 Category: Urology & Nephrology Authors: Christine K. Bailey, Stephen Caltabiano, Alexander R. Cobitz, Chun Huang, Kelly M. Mahar and Vickas V. Patel Tags: Research article Source Type: research